OBJECTIVE: A recent meta-analysis suggested that opioid substitution therapy (OST) increased uptake of antiretroviral treatment (ART) and HIV viral suppression. We modelled whether OST could improve the HIV prevention benefit achieved by ART among people who inject drugs (PWID). METHODS: We modelled how introducing OST could improve the coverage of ART across a PWID population for different baseline ART coverage levels. Using existing data on how yearly HIV-transmission risk is related to HIV plasma viral load, changes in the level of viral suppression across the population were used to project the relative reduction in yearly HIV-transmission risk achieved by ART, with or without OST, compared with if there was no ART - defined here as the prevention effectiveness of ART. RESULTS: Owing to OST use increasing the chance of being on ART and achieving viral suppression if on ART, the prevention effectiveness of ART for PWID on OST (compared with PWID not on OST) increases by 44, 31, or 20% for a low (20%), moderate (40%), or high (60%) baseline ART coverage, respectively. Improvements in the population-level prevention effectiveness of ART are also achieved across all PWID, compared with if OST was not introduced. For instance, if OST is introduced at 40% coverage, the population-level prevention effectiveness of ART could increase by 27, 20, or 13% for a low (20%), moderate (40%), or high (60%) baseline ART coverage, respectively. CONCLUSION: OST could improve the HIV prevention benefit of ART; supporting strategies that aim to concurrently scale-up OST with ART.
OBJECTIVE: A recent meta-analysis suggested that opioid substitution therapy (OST) increased uptake of antiretroviral treatment (ART) and HIV viral suppression. We modelled whether OST could improve the HIV prevention benefit achieved by ART among people who inject drugs (PWID). METHODS: We modelled how introducing OST could improve the coverage of ART across a PWID population for different baseline ART coverage levels. Using existing data on how yearly HIV-transmission risk is related to HIV plasma viral load, changes in the level of viral suppression across the population were used to project the relative reduction in yearly HIV-transmission risk achieved by ART, with or without OST, compared with if there was no ART - defined here as the prevention effectiveness of ART. RESULTS: Owing to OST use increasing the chance of being on ART and achieving viral suppression if on ART, the prevention effectiveness of ART for PWID on OST (compared with PWID not on OST) increases by 44, 31, or 20% for a low (20%), moderate (40%), or high (60%) baseline ART coverage, respectively. Improvements in the population-level prevention effectiveness of ART are also achieved across all PWID, compared with if OST was not introduced. For instance, if OST is introduced at 40% coverage, the population-level prevention effectiveness of ART could increase by 27, 20, or 13% for a low (20%), moderate (40%), or high (60%) baseline ART coverage, respectively. CONCLUSION: OST could improve the HIV prevention benefit of ART; supporting strategies that aim to concurrently scale-up OST with ART.
Authors: Andrew Edsall; Thanh Thuy Thi Dinh; Pham Phuong Mai; Kim Hoffman; Hang T Nguyen; Tong Thi Khuyen; Nguyen Thu Trang; Gavin Bart; Le Minh Giang; P Todd Korthuis Journal: J Behav Health Serv Res Date: 2021-04 Impact factor: 1.505
Authors: Jack Stone; Louisa Degenhardt; Jason Grebely; Sarah Larney; Frederick L Altice; Pavlo Smyrnov; Afarin Rahimi-Movaghar; Maryam Alavi; April M Young; Jennifer R Havens; William C Miller; Matthew Hickman; Peter Vickerman Journal: Lancet Psychiatry Date: 2021-02-25 Impact factor: 27.083
Authors: Javier A Cepeda; Annick Bórquez; Christopher Magana; Anh Vo; Claudia Rafful; Gudelia Rangel; María E Medina-Mora; Steffanie Strathdee; Natasha K Martin Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: Matthew Hickman; Colin Steer; Kate Tilling; Aaron G Lim; John Marsden; Tim Millar; John Strang; Maggie Telfer; Peter Vickerman; John Macleod Journal: Addiction Date: 2018-04-19 Impact factor: 6.526
Authors: Aniella Murphy; John Barbaro; Pablo Martínez-Aguado; Vanessa Chilunda; Matias Jaureguiberry-Bravo; Joan W Berman Journal: Front Immunol Date: 2019-10-18 Impact factor: 7.561
Authors: Jennifer P Jain; Akua O Gyamerah; Glenda N Baguso; Carol Dawson-Rose; Janet Ikeda; Glenn-Milo Santos Journal: Am J Mens Health Date: 2021 May-Jun
Authors: Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez Journal: Addiction Date: 2021-12-04 Impact factor: 7.256
Authors: Britt Skaathun; Annick Borquez; Antonio Rivero-Juarez; Sanjay R Mehta; Francisco Tellez; Manuel Castaño-Carracedo; Dolores Merino; Rosario Palacios; Juan Macías; Antonio Rivero; Natasha K Martin Journal: BMC Infect Dis Date: 2020-08-08 Impact factor: 3.090
Authors: Adam Trickey; Nadiya Semchuk; Tetiana Saliuk; Yana Sazonova; Olga Varetska; Josephine G Walker; Aaron G Lim; Jack Stone; Peter Vickerman Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396